



# Day-Storms, LLC

MEDICAL WRITING & RESEARCH

ACCURATE, EVIDENCE-BASED, AND TIMELY MEDICAL  
CONTENT

## GUIDELINES THIS WEEK...

National Cancer Comprehensive  
Network (NCCN)

AAP -- Periodicity schedule

ISTH -- hemophilia A & B

EANM/EANO/RANO/SNMMI --  
theranostics of meningiomas

# Weekly Guideline Update

Each Wednesday, I bring you news concerning updates to guidelines and recommendations by professional societies. This list is not all-inclusive, of course, but the following recent updates caught my attention.

If there are any guidelines I have missed this week that you would like to see included, please email me at [jerm@day-storms.com](mailto:jerm@day-storms.com).

## National Cancer Comprehensive Network (NCCN)

The NCCN guidelines can be found at [www.nccn.org](http://www.nccn.org).

- Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 2.2024 – The verbiage regarding elevated serum vitamin B12 and vitamin B12 have been removed from the guidelines. Likewise, the term “gene fusion rearrangements” has been replaced with “gene fusion”. The terms mixed lineage disease and mixed lineage blast phase disease are now mixed phenotype acute leukemias. The discussion section has been updated to reflect algorithmic changes.

- Neuroendocrine and Adrenal Tumors Version 1.2024 — The NCCN has extensively updated and modified the guidelines for neuroendocrine and adrenal tumors, including but not limited to revising the terms bronchopulmonary and bronchial to “lung”, changing “debulking” to “cytoreduction”, and modifying the language regarding primary treatment to first-line treatment. They have also extensively modified their recommendations regarding surveillance and imaging.

## American Academy of Pediatrics (AAP)

Within the 2024 Recommendations for Preventive Pediatric Health Care (Periodicity Schedule), the AAP is not recommending any changes to the guidelines.

## International Society on Thrombosis and Haemostasis (ISTH)

The ISTH guidelines for the treatment of congenital hemophilia A and B strongly recommend prophylactic treatment over episodic treatment for individuals with severe and moderately severe hemophilia A and B to reduce the risk of bleeding events. Additional conditional recommendations were given for patients with hemophilia A with specific criteria.

## European Association of Nuclear Medicine (EANM)/ Society of Nuclear Medicine and Molecular Imaging (SNMMI)/ European Association of Neurooncology (EANO)/ Response Assessment in Neurooncology Working Group (RANO)

The [EANM/SNMMI/EANO/RANO joint guidelines](#) recommend using radiolabeled somatostatin receptor (SSTR) ligands for both diagnostics and therapy (ie, “theranostics”) in meningiomas. SSTR PET imaging, utilizing tracers such as [68Ga]DOTATATE, [68Ga]DOTATOC, and [18F]SiTATE, is highlighted for its high sensitivity and specificity in detecting meningiomas, superior to MRI alone. It is particularly valuable for ambiguous MRI cases, tumor delineation in challenging anatomical locations, and detecting osseous involvement. For therapeutic purposes, SSTR-targeted peptide receptor radionuclide therapy (PRRT) using  $\beta$ -emitters like [177Lu]Lutetium or [90Y]Yttrium is noted for its potential benefits in treatment-refractory meningiomas, despite lacking randomized clinical trial evidence.